C. Q. Sacramento

This study shows that IAV or HA induces necroptosis in macrophages, contributing to cytokine storm and lung injury, and that anti-TNF treatment prevents these effects.

This study shows that atazanavir inhibits SARS-CoV-2 Mpro, effectively reducing replication of both B.1 and gamma variants in vitro and in vivo.

This study shows apixaban inhibits SARS-CoV-2 replication by targeting its Mpro protease non-competitively, with higher potency than boceprevir.

This paper shows mefloquine inhibits SARS-CoV-2 infection in relevant cells more effectively than chloroquine without promoting viral mutations.

This study identifies HCV NS5A inhibitors as SARS-CoV-2 exonuclease inhibitors and shows synergy in combination with polymerase inhibitors to enhance antiviral efficacy.

This study examines the effects of the cannabinoid agonist WIN 55,212-2 on inflammation and cell survival in human iPSC-derived cardiomyocytes infected with SARS-CoV-2, finding reduced cytokine levels and cytotoxic damage.

This study shows that inhibiting the Sigma-1 receptor with NE-100 reduces SARS-CoV-2 infection in human cardiomyocytes but also impairs cytoskeleton and contractility.

This study evaluates the in vitro antiviral activity of three Ebola and Marburg virus inhibitors against SARS-CoV-2 and explores their potential mechanisms of action.

This study shows that atazanavir inhibits SARS-CoV-2 replication and reduces pro-inflammatory cytokine production in vitro.

This study shows that lipid droplets support SARS-CoV-2 replication and inflammatory mediator production, with DGAT-1 inhibition reducing viral replication and inflammation.

This study produces potent equine antibodies against SARS-CoV-2 spike protein with high neutralizing titers, supporting a clinical trial for passive immunization therapy.

The paper shows elevated VIP plasma levels in severe COVID-19 patients correlate with survival and protective effects against SARS-CoV-2 in vitro.

This study evaluates the antiviral activity of daclatasvir and sofosbuvir against SARS-CoV-2 in vitro, showing inhibition of viral replication and associated pathologies.